TABLE 3.
Disease Type by Sample Size, Time-to-First Patient, Incidence, and Mortality
| Disease Site | # of Trials in Sample | Time to First Patient (months) | IRQ (months) | Min-Max (months) | Incidences (per 100,000) | Mortality (per 100,000 cases) |
|---|---|---|---|---|---|---|
| Gastrointestinal (including colon and pancreas) | 119 | 2 | 1–4 | 1–12 | 84.4 | 43.5 |
| Lung, Mediastinal and Pleural | 86 | 3 | 2–4 | 1–8 | 63.9 | 54.1 |
| Miscellaneous Neoplasm | 75 | 2 | 1–4 | 1–19 | 19.7 | 13.4 |
| Leukemia | 64 | 2 | 2–2 | 1–13 | 12.3 | 7.4 |
| Breast | 58 | 2 | 1–3.25 | 1–22 | 126.1 | 25 |
| Female Reproductive | 57 | 3 | 1–4 | 1–16 | 47.3 | 15.9 |
| Skin | 46 | 2 | 1–3 | 1–10 | 21.1 | 3.5 |
| Lymphoma | 44 | 4 | 2.25–5.75 | 1–18 | 22.2 | 7.8 |
| Central Nervous System | 41 | 3 | 1.5–4 | 1–14 | 6.5 | 4.4 |
| Male Reproductive (including prostate) | 36 | 3.5 | 1.25–6 | 1–16 | 168.4 | 27 |
| Kidney | 36 | 2 | 1–3 | 1–22 | 13.2 | 4.2 |
| Head and Neck | 35 | 3 | 2–5 | 1–14 | 14 | 3.9 |
| Urothelial Tract | 18 | 4 | 2–5.25 | 1–11 | 21.2 | 4.3 |
| Soft Tissue | 17 | 3 | 2–5.5 | 1–12 | 3.1 | 1.3 |
| Myeloma | 13 | 3 | 1.5–3.5 | 1–7 | 5.6 | 3.7 |
| Endocrine | 7 | 2 | 1–2 | 1–2 | 9.8 | 0.8 |
| AIDS-related | 5 | 5 | 1–10.5 | 1–12 | 1.2 | n/a |
| Bone | 2 | 2.5 | 2–3 | 2–3 | 0.9 | 0.9 |
| Immune Disorder | 2 | 4.5 | 4–5 | 4–5 | 0.7 | 0.8 |
| Germ Cell | 2 | 1.5 | 1–2 | 1–2 | 0.4 | 0.2 |